Samsung Biologics Signs Contract Worth 300.5 Billion KRW for Contract Manufacturing with Gilead Sciences
[Asia Economy Reporter Minji Lee] Samsung Biologics announced on the 7th that it has signed a contract for contract manufacturing of pharmaceuticals worth 300,586,757,400 KRW with Gilead Sciences. This is a correction of the contract with Immunomedics in 2018. Immunomedics was acquired by Gilead Sciences, and the contract amount was changed due to an increase in the client's volume. The contract amount increased from 184.4 billion KRW to 300.5 billion KRW.
The corrected contract amount corresponds to 64.69% of last year's sales, and the contract period is until January 31, 2025.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051414165763158_1778735817.jpg)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "This Strike Must Fail": Criticism Emerges Within Samsung as DS-MX Conflict Surfaces
- Individual Investors Absorb Foreign Sell-Off... Concerns Over Becoming "Cannon Fodder" Emerge
- Experts Shocked by Record Numbers: "Just the Tip of the Iceberg" — The Identity Behind the 90% Dominating Teens [Chuiyakgukga]⑨
- "No Cure Available, Spread Accelerates... Already 105 Dead, American Infected"
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
![Cheaper Than Mychew, but Nowhere to Be Found... Fears of a 'Pediatric Medical Crisis' as Drug Makers Halt Production [Why&Next]](https://cwcontent.asiae.co.kr/asiaresize/307/2026051910065268365_1779152813.jpg)
